Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 26, No 9 (March 20), 2008: pp. 1489-1495
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.1126

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by de Vries, E. G.E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by de Vries, E. G.E.

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography

Klaas P. Koopmans, Oliver C. Neels, Ido P. Kema, Philip H. Elsinga, Wim J. Sluiter, Koen Vanghillewe, Adrienne H. Brouwers, Pieter L. Jager, Elisabeth G.E. de Vries

From the Departments of Nuclear Medicine and Molecular Imaging, Medical Oncology, Pathology and Laboratory Medicine, and Endocrinology, University Medical Center Groningen, University of Groningen; Department of Radiology, Martini Hospital Groningen, the Netherlands

Corresponding author: Elisabeth G.E. de Vries, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands, e-mail: e.g.e.de.vries{at}int.umcg.nl

Purpose: To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers.

Patients and Methods: Carcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent 11C-5-hydroxytryptophan (11C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin (18F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information.

Results: In carcinoid tumor patients, per-patient analysis showed sensitivities for 11C-5-HTP PET, 18F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for 11C-5-HTP PET, 11C-5-HTP PET/CT, 18F-DOPA PET, 18F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients 18F-DOPA PET and 11C-5-HTP PET detected more lesions than SRS (P < .001). 11C-5-HTP PET was superior to 18F-DOPA PET in islet cell tumors (P < .0001). In all cases, CT improved the sensitivity of the nuclear scans.

Conclusion: 18F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and 11C-5-HTP PET/CT in islet cell tumor patients.

Supported by Grant No. 2003-2936 from the Dutch Cancer Society.

Presented in part at the 54th Annual Meeting of the Society of Nuclear Medicine June 2-6, 2007, Washington, DC.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online